### 1 Bi-directional Mendelian randomization and multi-phenotype GWAS show causality

## 2 and shared pathophysiology between depression and type 2 diabetes

- 3 Jared G Maina, MSc<sup>1,2\*</sup>, Zhanna Balkhiyarova, MD, PhD<sup>3,4,5\*</sup>, Arie Nouwen, PhD<sup>6</sup>, Igor
- 4 Pupko<sup>3,4</sup>, Anna Ulrich, PhD<sup>4</sup>, Mathilde Boissel, MSc<sup>1,2</sup>, Amélie Bonnefond, PhD<sup>1,2,4</sup>, Philippe
- 5 Froguel, MD PhD<sup>1,2,4</sup>, Amna Khamis, PhD<sup>1,2,4</sup>, Inga Prokopenko, PhD<sup>1,2,3,5\*</sup>, Marika
- 6 Kaakinen, PhD<sup>3,4,5\*</sup>

7	1. INSERM UMR 1283, CNRS UMR 8199, European Genomic Institute for Diabetes
8	(EGID), Institut Pasteur de Lille, F-59000 Lille, France
9	2. University of Lille, Lille University Hospital, Lille, F-59000, France
10	3. Department of Clinical & Experimental Medicine, University of Surrey, Guildford,
11	United Kingdom
12	4. Department of Metabolism, Digestion and Reproduction, Imperial College London,
13	London, UK
14	5. People-Centred Artificial Intelligence Institute, University of Surrey, Guildford, United
15	Kingdom
16	6. Department of Psychology, Middlesex University, London, UK
17	
18	* These authors contributed equally to this research.
19	
20	Corresponding authors:
21	
22	Dr Marika Kaakinen,
23	Section of Statistical Multi-Omics,
24	Department of Clinical and Experimental Medicine, University of Surrey
25	Leggett Building, Daphne Jackson Road, Manor Campus,
26	Guildford, Surrey, UK, GU2 7WG
27	Phone: +44(0)1483683365
28	Email:m.kaakinen@surrey.ac.uk
29	
30	Prof. Inga Prokopenko
31	Section of Statistical Multi-Omics,
32	Department of Clinical and Experimental Medicine, University of Surrey
33	Leggett Building, Daphne Jackson Road, Manor Campus,
34	Guildford, Surrey, UK, GU2 7WG
35	Phone: +44(0)1483684648
36	Email:i.prokopenko@surrey.ac.uk
37	
38	Dr Amna Khamis
39	European Genomic Institute for Diabetes - UMR 1283/8199
40	Pôle Recherche - 1er étage Aile Ouest
41	1, Place de Verdun, 59045 LILLE CEDEX
42	Phone: +33(0)3 74 00 8135

- 43 Email:amna.khamis@cnrs.fr
- 44 Running title (Limit 47 characters including spaces): MR and Multi-trait GWAS of diabetes
- 45 and depression
- 46 Word count (4128/4000)
- 47 Number of tables and figures in main text (2 tables, 2 figures)

#### 48 **Abstract (250/250 words)**

49 OBJECTIVE. Depression is a common co-morbidity of type 2 diabetes. However, the50 causality and underlying mechanisms remain unclear.

51 RESEARCH DESIGN AND METHODS. We applied bi-directional Mendelian 52 randomization (MR) to assess causality between type 2 diabetes and self-reported depression. 53 Using the UK biobank, we performed 1) GWAS, separately, and 2) multi-phenotype GWAS 54 (MP-GWAS) of type 2 diabetes (cases=19,344, controls=463,641) and depression, using two 55 depression definitions-clinically diagnosed major depressive disorder (MDD, cases=5,262, 56 controls=86,275) and self-reported depressive symptoms (PHQ-9, n=153,079). The FinnGen 57 study was used for replication for MDD (n=23,424) and type 2 diabetes (n=32,469). Based on 58 the results, we analyzed expression quantitative trait loci (eQTL) data from public databases 59 to identify target genes in relevant tissues. 60 RESULTS. MR demonstrated a significant causal effect of depression on type 2 diabetes 61 (OR=1.18[1.06-1.32], p=0.0024), but not in the reverse direction. GWAS of type 2 diabetes 62 and depressive symptoms did not identify any shared loci between them, whereas MP-GWAS 63 identified seven shared loci mapped to TCF7L2, CDKAL1, IGF2BP2, SPRY2, CCND2-AS1, 64 IRS1, CDKN2B-AS1. MDD did not yield genome-wide significant loci in either GWAS or 65 MP-GWAS. We found that most MP-GWAS *loci* had an eQTL, including SNPs implicating

the cell cycle gene *CCND2* in pancreatic islets and brain, and key insulin signaling gene *IRS1*in adipose tissue, suggesting a multi-tissue and pleiotropic underlying mechanism.

68 CONCLUSION. Our study reveals the complexity in the depression-diabetes relationship and
69 our results have important implications for a more efficient prevention of type 2 diabetes
70 from early adulthood when depressive symptoms usually occur.

# 71 **INTRODUCTION**

Type 2 diabetes is a disease characterized by chronic hyperglycemia and depression is a common co-morbidity, potentially due to common shared risk factors, such as lifestyle, early growth environment, psychotropic drugs, and neuro-endocrine dysfunction<sup>1</sup>. Whether the impact of type 2 diabetes on depression is stronger than the reverse remains to be defined. It has indeed been shown that depression, even at sub-clinical levels, increases the risk of incident type 2 diabetes by 25-60%<sup>2,3</sup>, whereas others have shown that type 2 diabetes increases the risk of depression by 40-60%<sup>4</sup>.

The causality of the associations from observational studies remains unclear due to unmeasured confounding and potential reverse causation. However, this could be circumvented in part through Mendelian randomization, an approach that assesses potential causality between phenotypes using genetic variants as instruments, since genes are allocated randomly at birth and are free of confounding<sup>5</sup>. To date, only one MR study from China has reported a possible causal link from type 2 diabetes to depression<sup>6</sup>, yet the reverse direction of causal link was not examined.

Recent large-scale genome-wide association studies (GWAS) for type 2 diabetes and depression have reported 403 and 102 associated genomic *loci* for these diseases, respectively<sup>7,8</sup>. Moreover, analyses based on the GWAS results support a positive genetic correlation ( $r_G$ ) between them<sup>7,8</sup>, suggesting shared genetic background. However, the majority of GWAS investigate each disease independently, without considering the genetic correlation between related phenotypes and their heritabilities.

Therefore, in this study, we addressed the causal relationship between depression and type 2 diabetes by conducting an MR study using summary statistics from recent GWAS of depression<sup>8</sup> and type 2 diabetes<sup>7</sup>. Additionally, we used the UK biobank (UKBB) to perform a multi-phenotype GWAS (MP-GWAS) for type 2 diabetes and depression to identify shared

- 96 genetic loci between the two diseases. For depression, we compared two assessment
- 97 approaches clinically diagnosed major depressive disorder (MDD) and depressive
- 98 symptoms based on self-report.

## 99 RESEARCH DESIGN AND METHODS

#### 100 Mendelian randomization

## 101 Summary statistics used

To test for causality between type 2 diabetes and depression, we performed a two-sample bidirectional MR, first using depression as a risk factor and type 2 diabetes as an outcome, then testing type 2 diabetes as a risk factor and depression as an outcome from two nonoverlapping datasets (**Supplementary Figure 1**). The single nucleotide polymorphisms (SNPs) used as genetic instruments for type 2 diabetes and self-reported depression were from recent large-scale European GWAS meta-analyses of the two diseases<sup>7,8</sup>.

## 108 **Two-sample bidirectional MR**

All MR analyses were conducted using the R software package  $TwoSampleMR v0.5.4^9$ . In the 109 110 type 2 diabetes GWAS summary statistics used, 95 single nucleotide polymorphisms (SNPs, inclusive of 6 proxy variants with a minimum  $r^{2} \ge 0.8$ ) out of the 102 independent ( $r^{2} < 0.01$ ) 111 112 depression SNPs were available. We excluded 7 palindromic SNPs (A/T or C/G) with 113 intermediate allele frequencies (minor allele frequency, MAF>45%) to ensure the effects of 114 the SNPs for the two phenotypes were aligned to the same forward strand allele. The genetic 115 instruments for type 2 diabetes included 403 genetic SNPs associated from a recent GWAS<sup>7</sup>. 116 In the depression summary statistics, 358 (inclusive of 4 proxy variants with a minimum  $r^{2} \ge 0.8$ ) out of 403 independent ( $r^{2} < 0.01$ ) type 2 diabetes SNPs were available for the analysis. 117 118 To obtain the causal estimate, we applied the inverse variance weighted (IVW) method<sup>5</sup>. We performed sensitivity MR analysis using weighted median (WM)<sup>10</sup>, MR-Egger regression<sup>11</sup>, 119 the simple mode<sup>12</sup>, and the weighted mode<sup>12</sup> methods to evaluate the potential violations of 120 121 the MR assumptions (Supplementary Methods) and confirm the robustness of the two-122 sample MR results from the IVW approach. F-statistic was used to evaluate the instrument 123 strength, where F>10 indicates the presence of a strong instrument. The F-statistics indicated

124	a good instrument strength for both type 2 diabetes (F-statistics = $61.26$ ) and depression (F-
125	statistics = 43).We assessed heterogeneity between the causal estimates from each SNP using
126	Cochran's Q-test. The sensitivity of causal inference to any individual genetic variant was
127	tested by leave-one-out analysis. We used the STROBE-MR reporting guideline for MR
128	studies to facilitate the readers' evaluation of our results <sup>13</sup> (Supplementary Table 1).
129	
130	Genome-wide association studies (GWAS) and Multi-phenotype GWAS (MP-GWAS)
131	Cohorts used
132	1) UK Biobank (UKBB)
133	We used data from the UK Biobank (UKBB, www.ukbiobank.ac.uk), which includes over
134	500,000 individuals from 22 centers across the United Kingdom. Study participants were
135	between 40 and 69 years at recruitment and provided information including body
136	measurements, biological samples, brain imaging data, socio-demographic and lifestyle
137	indicators. Genetic data was available for 488,377 individuals in the UKBB genotyped using
138	the UKBB BiLEVE array (n = 49,979) and the UKBB Axiom Array (n = $438,398$ ) <sup>14</sup> . The
139	genetic data was imputed using the Haplotype Reference Consortium <sup>15</sup> , the UK10K <sup>16</sup> and
140	1000 Genomes Phase 3 <sup>17</sup> , resulting in approximately 90 million variants available for
141	association testing. This research has been conducted under application number 35327 and all
142	participants gave informed consent during enrolment.
143	2) FinnGen
144	We utilized the FinnGen summary statistics for replication of our single- and multi-

phenotype association results (www.finngen.fi/fi). The June 2020 data freeze used in our analysis comprised of 135,638 individuals. Summary statistics for 1,801 phenotypes are publicly available for analysis. FinnGen study participants were genotyped using the Illumina and Affymetrix chip arrays (Illumina Inc., San Diego, and Thermo Fisher Scientific, Santa

Clara, CA, USA, https://www.thermofisher.com/). The data was then imputed using the SISu v3 imputation panel (http://sisuproject.fi) resulting in 16,962,023 variants available for association analysis. FinnGen study participants were genotyped using the Illumina and Affymetrix chip arrays (Illumina Inc., San Diego, and Thermo Fisher Scientific, Santa Clara, CA, USA, https://www.thermofisher.com/). Summary statistics provided for the FinnGen data association analyses were generated using the SAIGE software<sup>18</sup>.

## 155 **Phenotype definition**

### 156 **Type 2 diabetes**

157 In the UKBB, type 2 diabetes cases were defined if individuals self-reported to have a 158 diabetes diagnosis by a doctor, were on insulin medication one year after diagnosis, and were 159 at least 40 years old at the time of diagnosis. Individuals not meeting these criteria were 160 classified as controls. For both cases and controls, we excluded individuals with gestational 161 diabetes (Field 4041, code = 1), those younger than 40 years at the time of diagnosis (Field 162 2976) and individuals on insulin medication within the first year of diagnosis (Field 2986). 163 Sex discordant individuals (genotype vs. reported sex) were also excluded from the analyses. 164 We restricted our analyses to European individuals to limit confounding by ancestry. In total, 165 19,344 cases and 463,641 controls were available (Supplementary Table 2). 166 The GWAS summary statistics in the FinnGen study were based on the ICD10-coded type 2 167 diabetes (ICD code E11) on 32,469 individuals (case/control numbers not available). 168 Depression 169 We defined depression in two ways: ICD-10 coded major depressive disorder (MDD) based

- 170 on linked data from hospital records and self-reported depressive symptoms using the Patient
- 171 Health Questionnaire 9  $(PHQ-9)^{19}$ .

## 172 ICD-coded MDD

173 Individuals with a primary diagnosis of a depressive episode (ICD code F32) and recurrent 174 depression (ICD code F33) were defined as ICD-coded MDD cases (hereinafter referred to as 175 MDD). Individuals who answered "NO" to the questions "Have you ever seen a general 176 practitioner (GP) for nerves, anxiety, tension or depression?" (Field 2090) and "Have you 177 ever seen a psychiatrist for nerves, anxiety, tension or depression?" and "NO" to either 178 "depressed/down for a whole week" (Field 4598) or "Ever unenthusiastic/disinterested for a 179 whole week" were set as controls. Participants were excluded from the study if they had a 180 diagnosis of bipolar disorder (ICD codes F30, F31), mixed and other personality disorder 181 (F61) and schizophrenia (ICD code F20). Participants on antipsychotic medication (Field 182 20003) for 58 drugs were also excluded. In total, 5,262 cases and 86,275 controls were used 183 for the MDD phenotype (Supplementary Table 1). The proportion of MDD participants 184 who had a type 2 diabetes diagnosis are shown in Supplementary Table 3.

FinnGen study data had the ICD-10 codes F32 and F33 available for MDD. The GWAS summary statistics on MDD were based on a total of 23,424 individuals (case/control numbers not available).

# 188 **Depressive symptoms**

189 In UKBB, self-reported depressive symptoms over the previous two weeks (from the time of study enrolment) were assessed using the (PHQ-9)<sup>19</sup> questionnaire (Supplementary Table 190 191 4). It has been shown that the PHQ-9 questionnaire is invariant between people with and without diabetes<sup>20</sup> suggesting its interpretation is similar for both diabetes cases and controls. 192 193 Individuals missing responses for more than three PHQ-9 items were excluded from the 194 analysis. Missing PHQ-9 responses for the remaining individuals were imputed using the 195 ImputeSCOPA software (https://github.com/ImperialStatGen/imputeSCOPA), which 196 implements a random forest approach to impute missing items. The variables sex, age,

education qualification, body mass index (BMI), Townsend Deprivation Index<sup>21</sup> (an area-197 198 based measure of deprivation), genotyping array and eight principal components (PCs) were 199 included in the imputation model to improve the predictive accuracy of the imputation 200 (Supplementary Table 5). The sum of all nine PHQ-9 items after imputation for everyone 201 was used for quantitative association analysis. PHQ-9 data were available for 153,079 202 individuals (Supplementary Table 1). The proportion of individuals with PHQ-9 data and a 203 type 2 diabetes diagnosis are shown in Supplementary Tables 3 and 6. Symptom-based 204 depression phenotypes were unavailable in the FinnGen replication dataset.

205

206 **GWAS** 

We performed separate GWAS for type 2 diabetes, MDD and PHQ-9 in UKBB data with BOLT-LMM using a linear mixed model<sup>22</sup>. We adjusted for age, sex, array, BMI and the first 8 PCs. We analyzed common variants (MAF>5%), with imputation scores >0.4, Hardy-Weinberg Equilibrium (HWE) p-value>1×10<sup>-6</sup> and per SNP variant missingness<0.015. Manhattan plots were constructed using the *ggplot2* R package<sup>23</sup>. All analyses were performed on Human genome build 37. The statistical threshold for genome-wide significant SNPs (signals) used was  $p<5\times10^{-8}$ .

# 214 Multi-phenotype GWAS

We used MTAG (Multi-Trait Analysis of GWAS)<sup>24</sup>, which implements a generalized inverse-variance weighted meta-analysis, to increase the power for locus identification, improve SNP effect size estimates for type 2 diabetes and depressive phenotypes, and to identify potential multi-phenotype genetic variant effects. We used the summary statistics of the individual GWAS as inputs of MTAG. In UKBB, two MTAG models were tested - one with type 2 diabetes and MDD and another with type 2 diabetes and total PHQ-9 scores. This was to assess the consequence of using two different depression definition criteria (disease

diagnosis vs. disease symptoms) in an MP-GWAS approach. In FinnGen, only the first approach was applied due to data availability. For each MTAG model tested, MTAG outputs phenotype specific association statistics. To assess the robustness of MP-GWAS results, MTAG computes a maximum false discovery rate (maxFDR) statistic, a theoretical upper bound limit on the FDR for a GWAS<sup>24</sup>. Lower maxFDR values (maxFDR<5%) indicate robust results.

### 228 Expression quantitative trait loci (eQTL) analyses

To explore and identify target genes of the identified *loci*, we utilized several eQTL databases and datasets of relevant tissues. We extracted eQTL data from the GTEx Portal (https://gtexportal.org) for SNPs identified in our MP-GWAS, focusing on type 2 diabetes and depression relevant tissues (*i.e.*, brain, muscle, liver). In addition, as GTEx does not include data from pancreatic islets, a crucial tissue in type 2 diabetes pathogenicity, we utilized recent eQTL data from Tiger T2D Systems (http://tiger.bsc.es) obtained from > 500 brain-dead organ donor islets<sup>25</sup>. We extracted data for the seven shared SNPs identified in our

236 MP-GWAS from both eQTL studies (using nominal significance, p < 0.05).

Furthermore, we also used GTEx Version 7 transcriptome data<sup>26</sup> from European individuals 237 238 to identify eQTLs using our MP-GWAS summary statistics. We focused on relevant tissues 239 in 1) type 2 diabetes, namely liver, whole pancreas, muscle, adipose subcutaneous, adrenal 240 gland, whole blood, and 2) depression, including putamen basal ganglia, hippocampus, 241 substantia nigra, frontal cortex, amygdala, anterior cingulate cortex. For each tissue, the 242 predicted expression levels were then correlated with type 2 diabetes and PHQ-9 MTAG 243 summary statistics. P-values were corrected for multiple testing using Bonferroni correction 244 based on the number of genes tested per tissue (Supplementary Table 7). Genes where less 245 than 80% of the SNPs used in the model were found in the GWAS summary statistics were 246 excluded due to low reliability of association results. This analysis focused on type 2 diabetes

and PHQ-9 phenotypes only as the MDD phenotype was underpowered in both GWAS and

248 MP-GWAS.

249 **RESULTS** 

#### 250 Mendelian randomization

- 251 Our MR analysis revealed that depression was causally and positively associated with type 2 252 diabetes using the IVW method, with an OR of 1.18 (95%CI = 1.06-1.32; p = 0.0024). This 253 result was consistent with the WM sensitivity analyses, which showed an OR of 1.11 (95%CI 254 = 1.00-1.23, p = 0.043) (Figure 1 and Supplementary Figure 2A, Supplementary Table 255 8). The MR-Egger test showed no evidence of directional pleiotropy (p = 0.51), further 256 confirming the validity of the results. Additionally, the leave-one-out analysis showed no 257 outliers, suggesting that the observed association was not changed after removing any single 258 variant (Supplementary Figure 3). The Cochran's Q statistic for heterogeneity was 259 significant for the IVW method (Q=261.62,  $p=1.26 \times 10^{-20}$ ).
- We found no evidence of causality in the reverse direction between type 2 diabetes and depression, in the primary nor sensitivity analysis (IVW: OR = 0.999; CI = 0.99-1.01; p =

262 0.843) (Supplementary Figure 2B, Supplementary Table 9).

263

## 264 Genome wide association study in type 2 diabetes and depression

In order to identify whether type 2 diabetes and depression have a shared genetic etiology, we first performed a GWAS for both phenotypes, separately, using the UKBB. In total, for type 2 diabetes, we used 482,958 individuals (19,344 cases; 463,641 controls), and for depression we used 91,537 (5,262 cases; 86,276 controls) for MDD and 153,079 for PHQ-9. For type 2 diabetes, we identified 92 independent SNPs at 84 *loci*, of which 59 were replicated in the FinnGen with nominal significance (p<0.05) and consistent in direction of effect. For depression, we found three independent SNPs and *loci* for PHQ-9 and no SNPs associated

with the binary depression MDD trait in the UKBB. None of the GWAS SNPs identified in
type 2 diabetes were shared with depression (Supplementary Figure 4, Supplementary
Tables 10-12).

275

## 276 Multi-phenotype GWAS in UKBB

To improve the power to identify shared genetic variants between the two phenotypes, we performed the largest-to-date MP-GWAS of type 2 diabetes and depressive phenotypes in the UKBB using the respective GWAS summary statistics.

The MP-GWAS model with type 2 diabetes and MDD did not identify any significant associations for the binary definition of depression (MDD). For type 2 diabetes, we identified 71 independent signals at 66 *loci* (**Supplementary Figure 5 and 6, Supplementary Table 10**). The maxFDR for the type 2 diabetes and MDD MP-GWAS results was 1.5% and 7.7% respectively (**Supplementary Table 13**), indicating that the MDD results were likely inflated by the higher powered type 2 diabetes GWAS<sup>24</sup>. In FinnGen, the maxFDR were 11.5% and 25.5%, respectively, indicating highly inflated results for both traits.

287 In contrast, in the MP-GWAS model with type 2 diabetes and PHO-9, we identified eight 288 independent SNPs for PHQ-9 (compared to only three SNPs detected in GWAS) (Figure 2, 289 Supplementary Table 14), suggesting greater power for SNP discovery. Only the 290 CACNA2D2 locus was reported in both GWAS and MP-GWAS analyses for PHQ-9, 291 although with different, yet highly correlated lead SNPs (CACNA2D2, chromosome 2, 292  $SNP_{SP-GWAS}$  rs35335661,  $SNP_{MP-GWAS}$  rs1467916, r<sup>2</sup>=0.99). For type 2 diabetes, MP-GWAS 293 identified 53 SNPs at 50 loci (compared to 92 identified in the single-phenotype GWAS), of 294 which 24 *loci* were previously reported<sup>7</sup>. We replicated 37 type 2 diabetes signals in FinnGen 295 cohort (Supplementary Table 14).

In total, we found seven SNPs shared between type 2 diabetes and PHQ-9: rs7903146 (*TCF7L2*), rs7766070 (*CDKAL1*), rs1359790 (*SPRY2*), rs16860235 (*IGF2BP2*), rs76895963 (*CCND2-AS1*), rs2972144 (*IRS1*) and rs10811662 (*CDKN2B-AS1*) (**Table 1, Figure 2**). The maxFDR for type 2 diabetes and PHQ-9 after MP-GWAS were 0.98% and 1.8% respectively (**Supplementary Table 13**), indicating the results are robust and not influenced by the sample sizes of either GWAS.

## 302 eQTL analyses

303 To explore whether the seven SNPs shared between type 2 diabetes and self-reported 304 depression had a downstream functional impact, we first extracted eQTL data of the seven 305 identified SNPs using the 1) GTEx Portal in relevant tissues, including muscle, liver and 306 brain, and 2) the Tiger Portal for pancreatic islets. We found that of the seven shared SNPs 307 between type 2 diabetes and depression, six SNPs were associated with the expression of 308 nearby genes in relevant tissues (Table 2). This includes rs2972144-G risk allele associated 309 with a decreased expression of IRS1 and RP11-395N3.2 in visceral and subcutaneous adipose 310 and *RP11-395N3.1* in subcutaneous adipose tissue. Additionally, the rs76895963-T risk allele 311 was associated with the decreased expression of CCND2 in pancreatic islets, brain 312 cerebellum, skeletal muscle and subcutaneous adipose tissue, the decreased expression of its 313 antisense CCND2-ASI in pancreatic islets, brain cerebellum, basal ganglia and cortex, in 314 addition to CCND2-AS2 in the cerebellum. For pancreatic islets, we found an increased 315 expression of *NDUFA9* (Table 2).

In addition, using our MP-GWAS summary statistics, we tested in GTEx whether type 2 diabetes and PHQ-9 were associated with shared gene expression changes in several target tissues except for pancreatic islets as GTEx does not include data on that. This analysis identified additional target genes associated with both type 2 diabetes and PHQ-9 in eight tissues, consistent in direction of effect for both phenotypes: adipose subcutaneous (*IRS1*,

- 321 NCR3LG1, RP11-395N3.2), amygdala (HSPA1B), frontal cortex (CDKAL1), hypothalamus
- 322 (EIF2S2P3), skeletal muscle (HLA-DRA, RP11-370C19.2), substantia nigra (BETL1), and
- 323 whole blood (*EIF2S2P3*, *HLA-DRB1*) (Supplementary Figure 7, Supplementary Table 7
- and 15-17). Altogether, our data demonstrates a functional impact of our *loci* in several
- 325 related tissues.

### 326 CONCLUSIONS

We performed a large comprehensive study to investigate the relationship between type 2 diabetes and depression and found evidence for a causal positive association from depression to type 2 diabetes. We also performed a multi-phenotype GWAS of the two diseases, highlighting seven shared *loci* that target nearby genes in several target tissues. Altogether, our study provides novel insight into the underlying mechanisms linking the two diseases.

332 Our MR analysis, based on recent large-scale GWAS, provides evidence for causality on the 333 previously reported epidemiological associations from depression to type 2 diabetes<sup>3</sup>, but not 334 in the reverse direction. These findings are consistent with the pathophysiology for these diseases, whereby: 1) depression starts in adolescence or early adulthood<sup>27</sup>, whereas type 2 335 diabetes usually develops later<sup>28</sup>, 2) poor health habits among individuals with depression, 336 337 including smoking, physical inactivity and increased caloric intake (and associated 338 overweight), that are known to facilitate the development of type 2 diabetes<sup>3,29</sup>, 3) antidepressants frequently induce weight gain leading to type 2 diabetes <sup>29</sup>, and 4) the 339 340 systemic inflammation associated to increased stress hormone levels such as cortisol in the 341 context of depression also favors insulin resistance $^{30}$ .

342 While epidemiological studies also show increased risk of depression in people with type 2 diabetes<sup>4</sup>, we did not find evidence for causality in this relationship. Our evaluation of 343 344 instrument strength for the MR analysis suggests that the lack of this causal association is not 345 simply an issue of statistical power. A likely hypothesis is that the epidemiologically 346 observed association is confounded via other factors, which are not easily assessed in 347 epidemiological studies, such as psychosocial factors related to the painful management of a 348 middle-age chronic disease. Diabetes distress, the psychological burden caused by dealing 349 with having diabetes and having to care for it, has indeed been linked to depression<sup>31</sup>. 350 However, a large international longitudinal study of 14 countries has shown that only

351 depressive symptoms rather than MDD were predicted by diabetes distress one year after 352 diagnosis<sup>32</sup>.

353 In addition, our multi-phenotype GWAS revealed seven shared SNPs between type 2 diabetes 354 and self-reported depressive symptoms consistent in their directions of effect. It is interesting 355 to note that we did not find any shared SNPs associated with the binary MDD clinical 356 diagnosis and type 2 diabetes which we speculate could be due to several reasons: 1) that the 357 association between type 2 diabetes and depression is due to the less strictly defined 358 symptom-based depressive measures, and 2) the PHQ-9 is a continuous definition of 359 depression, and likely improves power compared to the binary MDD definition. Indeed, 360 previous studies showed that depression defined based on self-reported symptoms (minimal 361 phenotyping) rather than strict diagnostic criteria enables greater power for locus discovery in GWAS<sup>33</sup>. 362

363 Our eQTL analysis provided some clues to the underlying mechanisms linking the two 364 diseases. For instance, we found that the rs76895963-T risk allele was associated with the 365 decreased expression of CCND2 in the brain and pancreatic islets and insulin target tissues 366 (adipose and skeletal muscle), suggesting a pleiotropic effect of this locus. CCND2 encodes 367 Cyclin D2, which is involved in cell cycle regulation and with a role in pancreatic beta cell proliferation and insulin secretion<sup>34</sup>, consistent with our eQTL data showing a decreased 368 369 expression of the gene in pancreatic islets. Mutations in CCND2 have been described in 370 individuals with brain malformations<sup>35</sup>, confirming a role in maintaining brain growth, and 371 mouse knockout models of CCND2 have no brain neurogenesis and showed mild depression-372 like symptoms that were alleviated by anti-depressant chronic fluoxetine treatment $^{36}$ . In 373 addition, a recent study showed that neurogenesis in the brain may prevent depressive 374 symptoms. Indeed, these studies demonstrate a potential mechanism whereby CCND2 downregulation may halt this process<sup>37</sup>. In addition, the inhibition of *CCND2* in adipose tissue has 375

been shown to dysregulate adipocyte differentiation<sup>38</sup> and downregulated in obesity, suggesting a key role in maintaining adipocyte regeneration<sup>39</sup>. Therefore, we show that CCND2 has a multi-system and pleiotropic effect and could potentially mediate this relationship between type 2 diabetes and depression.

In addition, we found that the rs2972144-G risk allele was associated with decreased expression of *IRS1*, which encodes insulin receptor substrate 1, in adipose tissue. *IRS1* is a key signaling molecule necessary for insulin response in insulin target tissues and has been shown to be associated with insulin resistance<sup>40</sup>, a condition linked to both the development of type 2 diabetes and depression<sup>41</sup>.

Also, our eQTL analyses revealed further insights into the potential mechanisms underlying the relationship between type 2 diabetes and depression. Lower expression of *CDKAL1* in frontal cortex was associated both with type 2 diabetes and depressive symptoms. Although reported for bipolar disorder<sup>42,43</sup>, variation in *CDKAL1* has been associated with depressive phenotypes only in one previous study<sup>44</sup>. In addition, although we did not find an eQTL for this *locus* in pancreatic islets in our study, variation at *CDKAL1* has been implicated in type 2 diabetes and shown to reduce insulin secretion<sup>45</sup>.

392 We also found two target genes implicating the HLA region (HLA-DRA, HLA-DRB1) in the 393 shared pathogenesis of the two diseases, in blood and skeletal muscle. The role of depression 394 treatments, targeting the immune system, is very active<sup>46</sup>. Type 2 diabetes is also known to 395 have an impact on immune system with high blood glucose levels causing an inflammatory response<sup>47</sup>. While trying to underpin the molecular mechanisms within this potential shared 396 397 pathway, further studies on the type 2 diabetes-depression comorbidity should account also for the role of obesity with its known links with inflammation<sup>48</sup>, type 2 diabetes<sup>49</sup> and 398 399 suggested with depression<sup>50</sup>.

400 Our results highlight a shared genetic effect between the two phenotypes with plausible 401 biological significance that explain how environmental factors (*i.e.*, stress, lifestyle habits and 402 anti-depressant medication) could lead to the underlying co-morbidity. Therefore, we 403 speculate that our results could hold some clinical significance. For instance, the choice of 404 anti-depressant treatment offered to people with depression at risk of type 2 diabetes should 405 favor those that provide better glycemic control such as selective serotonin reuptake inhibitors (SSRIs)<sup>51</sup>. Additionally, people with depression should be encouraged, as part of 406 407 routine clinical care, to promote positive lifestyle habits such as increased physical activity, 408 adequate sleep, and a proper dietary regime.

409 This study exhibits several strengths. We report the first study to investigate the causal 410 relationship of type 2 diabetes and depression in both directions and performed the largest-to-411 date MP-GWAS for the two diseases. Our investigation highlights the ability of multi-412 phenotype approaches to reveal the shared associations in co-morbid diseases and further 413 confirms the power of large-scale datasets to uncover phenotype associations, including self-414 reported and continuous measures of diseases and their symptoms. However, there are some 415 limitations to be considered. Our main UKBB analyses on MDD did not yield any genome-416 wide significant signals in both GWAS and MP-GWAS and a validation in larger datasets is 417 needed. In addition, to effectively probe the credibility of the MTAG MP-GWAS results, 418 replication using another MP-GWAS method is needed as part of future analyses. Finally, we 419 could only replicate the type 2 diabetes-MDD analyses due to unavailability of publicly 420 available depressive symptoms GWAS and in the FinnGen cohort.

In conclusion, the shared *loci* between depressive symptoms and type 2 diabetes support a pleiotropic role in target tissues, providing insight into their pathophysiology and comorbidity, boosting our understanding of the pathogenesis of these two diseases. Additionally, self-reported depression/depressive symptoms may offer more in deciphering

19

- 425 the underlying co-morbidity with type 2 diabetes compared to the strictly defined MDD. The
- 426 causal effect of depression leading to the development of type 2 diabetes has important
- 427 implications for a more efficient prevention of type 2 diabetes from early adulthood.

## 428 ACKNOWLEDGEMENTS

429 This research has been conducted using the UK Biobank Resource under Application 430 Number 35327. This research was in part funded by the Diabetes UK (BDA number: 431 20/0006307), the European Union's Horizon 2020 research and innovation programme 432 (LONGITOOLS, H2020-SC1-2019-874739), Agence Nationale de la Recherche 433 (PreciDIAB, ANR-18-IBHU-0001), by the European Union through the "Fonds européen de 434 développement regional" (FEDER), by the "Conseil Régional des Hauts-de-France" (Hauts-435 de-France Regional Council) and by the "Métropole Européenne de Lille" (MEL, European 436 Metropolis of Lille).

## 437 **REFERENCES**

4381.Holt, R. I. G., Peveler, R. C. & Byrne, C. D. Schizophrenia, the metabolic syndrome439and diabetes. *Diabetic Medicine* vol. 21 515–523 Preprint at

440 https://doi.org/10.1111/j.1464-5491.2004.01199.x (2004).

- 441 2. Mezuk, B., Eaton, W. W., Albrecht, S. & Golden, S. H. Depression and Type 2
- 442 Diabetes Over the LifespanA meta-analysis. *Diabetes Care* **31**, 2383–2390 (2008).
- 443 3. Rotella, F. & Mannucci, E. Depression as a Risk Factor for Diabetes. *J Clin Psychiatry*444 74, 31–37 (2013).
- 445 4. Nouwen, A. *et al.* Type 2 diabetes mellitus as a risk factor for the onset of depression: 446 a systematic review and meta-analysis. *Diabetologia* **53**, 2480–2486 (2010).
- Lawlor, D. A., Harbord, R. M., Sterne, J. A. C., Timpson, N. & Smith, G. D.
  Mendelian randomization: Using genes as instruments for making causal inferences in epidemiology. *Stat Med* 27, 1133–1163 (2008).
- 450 6. Xuan, L. *et al.* Type 2 diabetes is causally associated with depression: a Mendelian randomization analysis. *Front Med* 12, 678–687 (2018).
- 452 7. Mahajan, A. *et al.* Fine-mapping type 2 diabetes loci to single-variant resolution using
  453 high-density imputation and islet-specific epigenome maps. *Nat Genet* 50, 1505–1513
  454 (2018).
- 455 8. Howard, D. M. *et al.* Genome-wide meta-analysis of depression identifies 102
  456 independent variants and highlights the importance of the prefrontal brain regions. *Nat*457 *Neurosci* 22, 343–352 (2019).
- 458 9. Hemani, G. *et al.* The MR-base platform supports systematic causal inference across
  459 the human phenome. *Elife* 7, (2018).
- 460 10. Bowden, J., Davey Smith, G., Haycock, P. C. & Burgess, S. Consistent Estimation in
  461 Mendelian Randomization with Some Invalid Instruments Using a Weighted Median
  462 Estimator. *Genet Epidemiol* 40, 304–314 (2016).
- 463 11. Bowden, J., Smith, G. D. & Burgess, S. Mendelian randomization with invalid
  464 instruments: effect estimation and bias detection through Egger regression. *Int J*465 *Epidemiol* 44, 512–525 (2015).
- 466 12. Hartwig, F. P., Smith, G. D. & Bowden, J. Robust inference in summary data
  467 Mendelian randomization via the zero modal pleiotropy assumption. *Int J Epidemiol*468 46, 1985–1998 (2017).
- 469 13. Skrivankova, V. W. *et al.* Strengthening the reporting of observational studies in
  470 epidemiology using mendelian randomisation (STROBE-MR): explanation and
  471 elaboration. *BMJ* **375**, (2021).
- 472 14. Bycroft, C. *et al.* The UK Biobank resource with deep phenotyping and genomic data.
  473 *Nature* 562, 203–209 (2018).
- 474 15. McCarthy, S. *et al.* A reference panel of 64,976 haplotypes for genotype imputation.
  475 *Nat Genet* 48, 1279–1283 (2016).
- 476 16. Huang, J. *et al.* Improved imputation of low-frequency and rare variants using the
  477 UK10K haplotype reference panel. *Nat Commun* (2015) doi:10.1038/ncomms9111.
- 478 17. Auton, A. *et al.* A global reference for human genetic variation. *Nature* vol. 526 68–74
  479 Preprint at https://doi.org/10.1038/nature15393 (2015).
- 480 18. Zhou, W. *et al.* Scalable generalized linear mixed model for region-based association
  481 tests in large biobanks and cohorts. *Nat Genet* 52, 634–639 (2020).
- 482 19. Kroenke, K., Spitzer, R. L. & Williams, J. B. The PHQ-9: validity of a brief depression
  483 severity measure. *J Gen Intern Med* 16, 606–13 (2001).
- 484 20. Nouwen, A. *et al.* Measurement invariance testing of the patient health questionnaire-9
  485 (PHQ-9) across people with and without diabetes mellitus from the NHANES, EMHS
  486 and UK Biobank datasets. *J Affect Disord* 292, 311–318 (2021).

487 488	21.	Townsend, P., Phillimore, P. & Beattie, Alastair. Health and deprivation : inequality and the North, 211 (1988).					
489	22.	Loh, P. R. <i>et al.</i> Efficient Bayesian mixed-model analysis increases association power					
490		in large cohorts. Nat Genet (2015) doi:10.1038/ng.3190.					
491	23.	Wickham, Hadley. ggplot2: Elegant Graphics for Data Analysis. (Springer-Verlag					
492		New York, 2016).					
493	24.	Turley, P. et al. Multi-trait analysis of genome-wide association summary statistics					
494		using MTAG. Nat Genet 50, 229–237 (2018).					
495 496	25.	Alonso, L. <i>et al.</i> TIGER: The gene expression regulatory variation landscape of human pancreatic islets. <i>Cell Rep</i> <b>37</b> , (2021).					
497	26.	Lonsdale, J. et al. The Genotype-Tissue Expression (GTEx) project. Nature Genetics					
498		vol. 45 580-585 Preprint at https://doi.org/10.1038/ng.2653 (2013).					
499	27.	Solmi, M. et al. Age at onset of mental disorders worldwide: large-scale meta-analysis					
500		of 192 epidemiological studies. Molecular Psychiatry 2021 1-15 (2021)					
501		doi:10.1038/s41380-021-01161-7.					
502	28.	Bruce, D. G. et al. Lifetime depression history and depression risk in type 2 diabetes:					
503		A case-control study. J Diabetes Complications 30, 38–42 (2016).					
504	29.	Strine, T. W. et al. The association of depression and anxiety with obesity and					
505		unhealthy behaviors among community-dwelling US adults. Gen Hosp Psychiatry 30,					
506	•	127–137 (2008).					
507	30.	Golden, S. A review of the evidence for a neuroendocrine link between stress,					
508		depression and diabetes mellitus. Curr Diabetes Rev 3, 252–259 (2007).					
509	31.	Fisher, L. <i>et al.</i> Clinical Depression Versus Distress Among Patients With Type 2					
510	22	Diabetes Not just a question of semantics. <i>Diabetes Care</i> <b>30</b> , 542–548 (2007).					
511	32.	Lloyd, C. E. <i>et al.</i> Factors associated with the onset of major depressive disorder in					
512		adults with type 2 diabetes living in 12 different countries: results from the					
515	22	Coi N at al Minimal phonotyping yields genome wide association signals of low					
515	55.	specificity for major depression. Nat Ganat 52, A37, AA7 (2020)					
516	34	Stemateris R E <i>et al.</i> Glucose Induces mouse $\beta_{-cell}$ proliferation via IRS2 MTOR					
517	54.	and cyclin D2 but Not the insulin recentor <i>Diabetes</i> 65 981–995 (2016)					
518	35	Pirozzi F <i>et al.</i> Proximal variants in CCND2 associated with microcephaly short					
519	20.	stature, and developmental delay: A case series and review of inverse brain growth					
520		phenotypes. Am J Med Genet A 185, 2719–2738 (2021).					
521	36.	Jedvnak, P., Kos, T., Sandi, C., Kaczmarek, L. & Filipkowski, R. K. Mice with ablated					
522		adult brain neurogenesis are not impaired in antidepressant response to chronic					
523		fluoxetine. J Psychiatr Res 56, 106–111 (2014).					
524	37.	Svoboda, E. Brain-cell growth keeps mood disorders at bay. <i>Nature</i> <b>608</b> , S48–S49					
525		(2022).					
526	38.	Hishida, T., Naito, K., Osada, S., Nishizuka, M. & Imagawa, M. Crucial roles of D-					
527		type cyclins in the early stage of adipocyte differentiation. Biochem Biophys Res					
528		<i>Commun</i> <b>370</b> , 289–294 (2008).					
529	39.	Molina-Ayala, M. A. et al. Expression of obesity- and type-2 diabetes-associated					
530		genes in omental adipose tissue of individuals with obesity. Gene 815, 146181 (2022).					
531	40.	DeFronzo, R. A. & Tripathy, D. Skeletal Muscle Insulin Resistance Is the Primary					
532		Defect in Type 2 Diabetes. Diabetes Care 32, S157 (2009).					
533	41.	Lyra e Silva, N. de M. et al. Insulin resistance as a shared pathogenic mechanism					
534		between depression and type 2 diabetes. Frontiers in Psychiatry vol. 10 57 Preprint at					
535		https://doi.org/10.3389/fpsyt.2019.00057 (2019).					

536	42.	Nurnberger, J. I. et al. Identification of pathways for bipolar disorder: A meta-analysis.
537		JAMA Psychiatry <b>71</b> , 657–664 (2014).
538	43.	Swaminathan, S. et al. Characteristics of Bipolar I patients grouped by externalizing
539		disorders. J Affect Disord 178, 206–214 (2015).
540	44.	Haljas, K. et al. Bivariate Genome-Wide Association Study of Depressive Symptoms
541		With Type 2 Diabetes and Quantitative Glycemic Traits. <i>Psychosom Med</i> 80, 242–251
542		(2018).
543	45.	Kirchhoff, K. et al. Polymorphisms in the TCF7L2, CDKAL1 and SLC30A8 genes are
544		associated with impaired proinsulin conversion. <i>Diabetologia</i> <b>51</b> , 597–601 (2008).
545	46.	Lee, C. H. & Giuliani, F. The Role of Inflammation in Depression and Fatigue. Front
546		<i>Immunol</i> <b>10</b> , 1696 (2019).
547	47.	Berbudi, A., Rahmadika, N., Tjahjadi, A. I. & Ruslami, R. Type 2 Diabetes and its
548		Impact on the Immune System. Curr Diabetes Rev 16, 442–449 (2019).
549	48.	Ellulu, M. S., Patimah, I., Khaza'ai, H., Rahmat, A. & Abed, Y. Obesity and
550		inflammation: the linking mechanism and the complications. Archives of Medical
551		<i>Science</i> <b>13</b> , 851–863 (2017).
552	49.	Al-Goblan, A. S., Al-Alfi, M. A. & Khan, M. Z. Mechanism linking diabetes mellitus
553		and obesity. Diabetes Metab Syndr Obes 7, 587-591 (2014).
554	50.	Blasco, B. V., García-Jiménez, J., Bodoano, I. & Gutiérrez-Rojas, L. Obesity and
555		Depression: Its Prevalence and Influence as a Prognostic Factor: A Systematic Review.
556		<i>Psychiatry Investig</i> <b>17</b> , 715–724 (2020).
557	51.	Deuschle, M. Effects of antidepressants on glucose metabolism and diabetes mellitus
558		type 2 in adults. Curr Opin Psychiatry 26, 60–65 (2013).
559		
560		

**Type 2 diabetes** PHO-9 NEAREST CHR **SNP** BP GENE EA NEA EAF ВЕТА SE Р ВЕТА SE Р 4.89x10<sup>-16</sup> 2 rs2972144 IRS1  $1.80 \times 10^{-08}$ 227101411 G 0.65 0.0031 0.00038 0.065 0.012 А 3 rs16860235 IGF2BP2  $1.41 \times 10^{-30}$  $4.19 x 10^{-17}$ 185512361 G 0.28 0.0046 0.00040 0.103 0.012 Α  $7.79 \times 10^{-29}$ CDKAL1\*  $1.24 \times 10^{-12}$ 6 rs7766070 20686573 А С 0.26 0.0046 0.00041 0.103 0.014 9 rs10811662  $7.88 \times 10^{-25}$ 4.30x10<sup>-09</sup> CDKN2B-AS1 22134253 G 0.83 0.0049 0.00048 0.09 0.015 Α 6.88x10<sup>-178</sup>  $1.68 \times 10^{-64}$ 10 rs7903146 114758349 TCF7L2 Т С 0.29 0.011 0.00040 0.21 0.012 12 rs76895963 CCND2-AS1  $3.08 \times 10^{-27}$ 1.91x10<sup>-11</sup> Т G 0.98 0.015 0.29 0.043 4384844 0.0014 13 rs1359790 SPRY2  $8.54 x 10^{-17}$  $5.91 \times 10^{-10}$ 80717156 G 0.72 0.0035 0.00040 0.076 0.012 A

Table1. Summary statistics of the seven shared loci between type 2 diabetes and PHQ-9 after MP-GWAS

\* Different SNP for PHQ-9 (rs2206734, Position-20694884, Effect Allele-G, Non-effect

Allele-C; In high LD with type 2 diabetes SNP=R2=0.544)

561 Legend: CHR=chromosome, BP=base pair position (genome build 37), EA=effect allele, NEA=non-effect

allele, EAF=effect allele frequency

563

564	Table 2. Target genes of SNPs shared type 2 diabetes and depressive symptoms in relevant target tissues.
565	

								Organ donors	
CHR	SNP	BP	Nearest gene	EA	NEA	Tissue	Effect direction	Gene target	Р
2	rs2972144	227101411	IRS1	G	А	Adipose -	Negative	IRSI	2.60x10 <sup>-16</sup>
						Subcutaneous Adipose - Subcutaneous	Negative	RP11-395N3.2	5.70x10 <sup>-09</sup>
						Adipose - Subcutaneous	Negative	RP11-395N3.1	1.70x10 <sup>-07</sup>
						Adipose - Visceral	Negative	IRS1	2.80x10 <sup>-11</sup>
						Adipose - Visceral	Negative	RP11-395N3.2	1.6x10 <sup>-06</sup>
3	rs16860235	185512361	IGF2BP2	А	G	Pancreatic islets	Negative	IGF2BP2	3.94x10 <sup>-5</sup>
						Pancreatic islets	Negative	C3orf70	0.028
						Pancreatic islets	Positive	EIF4A2	0.045
6	rs7766070	20686573	CDKAL1	А	С	Pancreatic islets	Positive	LINC005811	0.049
9	rs10811662	22134253	CDKN2A- AS1	G	А	Pancreatic islets	Positive	MTAP	0.038
						Pancreatic islets	Positive	CDKN2A	0.00099
						Pancreatic islets	Positive	CDKN2B-AS1	$1.54 \times 10^{-7}$
10	rs7903146	114758349	TCF7L2	Т	С	Pancreatic islets	Positive	TCF7L2	0.0029
12	rs76895963	4384844	CCND2- AS1	Т	G	Pancreatic islets	Negative	CCND2	1.68 x 10 <sup>-6</sup>
						Pancreatic islets	Negative	CCND2-AS1	0.017
						Pancreatic islets	Positive	NDUFA9	0.039
						Brain - Cerebellum	Negative	CCND2	7.90x10 <sup>-22</sup>
						Brain - Cerebellum	Negative	CCND2-AS1	2.10x10 <sup>-16</sup>
						Brain - Cerebellum	Negative	CCND2-AS2	$1.00 \mathrm{x10^{-08}}$
						Brain - Nucleus accumbens (basal	Negative	CCND2-AS1	2.70x10 <sup>-07</sup>
						ganglia) Brain - Putamen (basal ganglia)	Negative	CCND2-ASI	0.000008
						Brain - Cortex	Negative	CCND2-ASI	0.000011
						Muscle - Skeletal	Negative	CCND2	9.30x10 <sup>-15</sup>
						Adipose - Subcutaneous	Negative	CCND2	2.70x10 <sup>-10</sup>
13	rs1359790	80717156	SPRY2	G	Α	NA	NA	NA	NA

566

Legend: CHR=chromosome, BP=base pair position (genome build 37), EA=effect allele, NEA=non-effect

567Legend: CHR=chromosome, BP=ba568allele, EAF=effect allele frequency

569	Figure legends
-----	----------------

- 570 **Figure 1**. Forest plot showing the Mendelian randomization analysis results between
- 571 depression (exposure) and type 2 diabetes (type 2 diabetes). The odds ratio (OR), their
- 572 95% confidence intervals and *P*-values are shown.
- 573 Figure 2. Manhattan plots of type 2 diabetes (A) and PHQ-9 (B) after MP-GWAS in
- 574 UK Biobank. The red horizontal line shows genome-wide significance threshold
- 575  $(P < 5 \times 10^{-8})$ . Grey dashed horizontal lines show suggestive genome-wide significance
- 576 threshold ( $P < 1 \times 10^{-5}$ ). The shared loci are annotated.





PHQ9

60 -

